Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans-Reference-Cited by-同舟云学术

Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans

Published:2023-06-26 Issue:4 Volume:48 Page:411-425
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

Piel Isabel,Engelen Anna,Lang Dieter,Schulz Simone I.,Gerisch Michael,Brase Christine,Janssen Wiebke,Fiebig Lukas,Heitmeier Stefan,Kanefendt Friederike^ORCID

Funder

Bayer

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s13318-023-00838-4.pdf

Reference22 articles.

1. Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340–7. https://doi.org/10.1161/CIRCRESAHA.115.306841.

2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8. https://doi.org/10.1161/01.str.22.8.983.

3. Marano G, Vaglio S, Pupella S, et al. How we treat bleeding associated with direct oral anticoagulants. Blood Transfus. 2016;14(5):465–73. https://doi.org/10.2450/2016.0180-15.

4. Gailani D, Gruber A. Factor XI as a therapeutic target. Arterioscler Thromb Vasc Biol. 2016;36(7):1316–22. https://doi.org/10.1161/ATVBAHA.116.306925.

5. Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010;116(22):4684–92. https://doi.org/10.1182/blood-2010-04-277798.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pharmacokinetic and pharmacodynamic evaluation of asundexian: a novel factor XIa inhibitor for stroke prevention;Expert Opinion on Drug Metabolism & Toxicology;2024-09-11

2. Laboratory Evaluation of Interferences Associated with Factor XIa Inhibitors Asundexian and Milvexian in Routine Coagulation Assays;Diagnostics;2024-09-09

3. Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data;Clinical and Translational Science;2024-07-31

4. Design and synthesis of novel factor XIa Inhibitors with bicyclic isoquinoline and naphthalene fragments;Medicinal Chemistry Research;2024-05-30

5. Drug–Drug Interactions of FXI Inhibitors: Clinical Relevance;Hematology Reports;2024-03-21